Phase I study of Tiragolumab in patients with advanced solid tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224926

Enrollment

Registered

2019-10-21

Start date

2019-11-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumor

Interventions

investigational material(s) Generic name etc : Tiragolumab INN of investigational material : Tiragolumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - ECOG Performance Status of 0 or 1 - Histologically or cytologically documented solid tumors - Evaluable lesion by image

Exclusion criteria

Exclusion criteria: - History of severe adverse reaction by treatment with previous cancer immunotherapy - History or complication of autoimmune disease - Meningeal metastasis or metastasis to the central nervous system requiring treatment or accompanied by symptoms

Design outcomes

Primary

Measure	Time frame
safety, pharmacokinetics Observation/Inspection	—

Secondary

Measure	Time frame
efficacy, other Observation/Inspection Endpoints Other (Immunogenicity)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026